This study is recruiting patients receiving cancer treatment that includes a type of drug called an "alkylating agent", which may cause side effects such as damage to the ovaries (female reproductive organs). The goal of the study is to determine the feasibility of conducting a cross network, multi-site, randomized clinical trial of triptorelin among newly diagnosed adolescent and young adult (AYA) female cancer patients age <40 years (exclusive of breast cancer). The triptorelin used in this study may affect how different parts of your body work such as your liver, kidneys, heart, and blood. Participants will receive the medications through an intramuscular (IM) injection in their arm. Study participation is expected to last up to three years.

This study will enroll patients with different types of cancer, as well as healthy patients with no history of cancer, into four cohorts to collect urine and/or blood samples only. The study will collect biospecimen samples to support further development of a urine-based ctDNA test. The study will enroll a total of 920 patients over 4 years.

We will gather feedback from healthcare providers and pregnant or up to two years postpartum adult women to better understand their needs and experiences related to traumatic stress and alcohol use during pregnancy. We will conduct focus groups with maternal health and mental health professionals, as well as conduct 60-minute interviews along with a survey/questionnaire with pregnant women who are experiencing both alcohol-related challenges and trauma-related symptoms. What we learn from these conversations will help us tailor services to address the unique needs of women during pregnancy and the postpartum period.

Up to 40% of people who want to reduce their drinking have thought about suicide. However, currently there are no treatments that create a plan to manage cravings for alcohol and to manage suicide ideation. This study consists of three studies: Study 1 aims to conduct interviews with adults with lifetime alcohol misuse and thoughts of suicide and with providers who have worked with patients with alcohol misuse. The interviews obtain feedback on a newly developed brief (single appointment) treatment for alcohol craving and thoughts of suicide. Study 2 aims to pilot test the single-appointment treatment and 1 week of text messages with adults with recent alcohol misuse and recent thoughts of suicide. Adults will provide feedback in a brief interview. Study 3 aims to test the single-appointment treatment and 4 weeks of text messages with adults with recent alcohol misuse and recent thoughts of suicide. Specifically, different types of text messages will be tested.

This study is to compare the usual treatment (radiation plus temozolomide alone) to using the study treatment (usual treatment plus the study drug, vorasidenib). The addition of the study drug, vorasidenib, to the usual treatment could shrink or stabilize your cancer. The study drug is FDA (Food and Drug Administration approved. The study drug will be given orally. The study will randomize (the computer will pick the group that the participant will be enrolled in) participant to Group 1 or Group 2. Participants can expect to be on the trial for 10 years or more. There will 4 participants enrolled locally.

The purpose of this research study is to learn how the nervous system functions in individuals with and without spinal cord injury, and examine how this relates to function. As part of this study, procedures may include nerve stimulation, brain stimulation, imaging (MRI), walking assessments, measures of brain activity, sensation testing, measures of arm or leg function, and self-report measures regarding daily activities and quality of life. The duration of participation depends on the number of procedures to which an individual is consented.

The study will examine the effects of a 10-week resistance training program, with or without creatine monohydrate supplementation, on changes in body composition, physical function, cancer-related fatigue, quality of life, and symptom burden in head and neck cancer (HNC) survivors. All participants will undergo screening that includes completion of questionnaires, exercise testing and physical function assessments before and after the treatment period as well as at a 10-week follow up evaluation. We hypothesize that group that completes resistance training with creatine monohydrate supplementation will achieve greater improvements in body composition, physical function, cancer-related fatigue, quality of life, and symptom burden when compared to the group that completes resistance training alone.

Researchers at the Medical University of South Carolina are studying speech and language in people with Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA), and in healthy adult volunteers. These conditions can change how a person speaks and uses language, and the changes may differ from one condition to another. The study uses a tablet-based set of short speech and language tasks, called SLANG, together with computer software that measures features of the recorded speech, such as pitch, timing, and word choice. Participants also complete standard speech, language, and thinking tests and a brief exam by a neurologist, which researchers compare against the tablet measurements. The purpose of this study is to gather early research data: to build a database of these measurements across the groups, to check whether the tablet captures them reliably, and to explore whether they differ between conditions. SLANG is not used to diagnose participants or to guide their medical care in this study. The long-term goal of this research is to develop a tool that could someday help clinicians recognize and tell these conditions apart earlier, but testing such a tool for diagnosis is beyond the scope of the current study.

This study will include 2 groups of participants with subjective cognitive complaints (1) individuals diagnosed with Ehlos Danlos Syndrome (EDS), and older adults without EDS. Participants will complete a 6-week cognitive + occupational therapy tele-rehabilitation program (first 4 weeks: 2 sessions per week, last 2 weeks: 1 session per week), for a total of 10 treatment visits. This study integrates cognitive training with an evidence based OT-led tele-rehabilitation program. We will complete a comprehensive battery of cognitive assessments as well as participant reported outcome measures at the pre and post visits to characterize subjective cognitive difficulties and test the feasibility and initial effect of this personalized intervention.

The purpose of the Re-Spire Study is to help researchers learn more about the efficacy and long-term safety and tolerability of the research drug L606 in participants with PH-ILD.
There are two phases of the Re-Spire Study participants can potentially join with the second phase starting directly after the first phase ends. The first phase is called the "Blinded Treatment Phase" (BTP). This is the "double-blind," assigned by chance portion of the study and will last approximately 28 weeks (a 30-day Screening period followed by a 24-week study period). The second phase of the Re-Spire Study is called the "Open Label Extension Phase" (OLEP). This phase is optional. It is called "open-label" because there is no placebo and everyone who joins will take the active study drug, L606.
About 350 participants will take part in this research study from around 120 study centers or research sites in various countries or regions.